Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2A6 | P11509 | 4/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 4/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 3/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | ACHE | P22303 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4061977 | 0.72 | ATM (0.38) | CYP2A6LMNAKDM4EALDH1A1GAA | |
| SCHEMBL30467697 | 0.70 | LMNA (0.35) | CYP2A6CYP1A2LMNAKDM4EALDH1A1 | |
| SCHEMBL26772160 | 0.70 | LMNA (0.35) | CYP2A6CYP1A2LMNAKDM4EALDH1A1 | |
| SCHEMBL6991227 | 0.69 | ERN1 (0.36) | CYP2A6TDP1LMNAKDM4EALDH1A1 | |
| SCHEMBL10391567 | 0.68 | CYP2A6 (0.63) | CYP2A6CYP1A2TDP1ALDH1A1GAA | |
| SCHEMBL26205353 | 0.67 | CYP1A2 (0.42) | CYP2A6CYP1A2TDP1LMNAKDM4E | |
| SCHEMBL25252937 | 0.67 | CYP1A2 (0.52) | CYP2A6CYP1A2TDP1LMNAKDM4E | |
| SCHEMBL3698199 | 0.67 | CYP1A2 (0.54) | CYP2A6CYP1A2TDP1LMNAKDM4E | |
| SCHEMBL4071402 | 0.67 | F7 (0.33) | CYP2A6 | |
| SCHEMBL11495194 | 0.66 | CYP1A2 (0.46) | CYP2A6CYP1A2TDP1LMNAKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200031811-A1 | SUBSTITUTED MONO- AND POLYAZANAPHTHALENE DERIVATIVES AND THEIR USE | BASILEA PHARM INT AG (CH) | 2020-01-30 | — | — | US | disclosed |
| US-20180002321-A1 | SUBSTITUTED MONO- AND POLYAZANAPHTHALENE DERIVATIVES AND THEIR USE | Basilea Pharmaceutica International AG (CH) | 2018-01-04 | — | — | US | disclosed |
| US-20180002321-A1 | SUBSTITUTED MONO- AND POLYAZANAPHTHALENE DERIVATIVES AND THEIR USE | Basilea Pharmaceutica International AG (CH) | 2018-01-04 | — | — | US | disclosed |
| EP-3256217-A1 | SUBSTITUTED MONO- AND POLYAZANAPHTHALENE DERIVATIVES AND THEIR USE | Basilea Pharmaceutica International AG (CH) | 2017-12-20 | — | — | EP | disclosed |
| WO-2016128465-A1 | SUBSTITUTED MONO- AND POLYAZANAPHTHALENE DERIVATIVES AND THEIR USE | BASILEA PHARMACEUTICA AG (CH) | 2016-08-18 | — | — | WO | disclosed |
| WO-2016128465-A1 | SUBSTITUTED MONO- AND POLYAZANAPHTHALENE DERIVATIVES AND THEIR USE | BASILEA PHARMACEUTICA AG (CH) | 2016-08-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180002321-A1 | SUBSTITUTED MONO- AND POLYAZANAPHTHALENE DERIVATIVES AND THEIR USE | CBR3, SCO2, CBR1 | CYP2A6 767/4885CYP1A2 296/4885TDP1 3341/4885 |
| US-20200031811-A1 | SUBSTITUTED MONO- AND POLYAZANAPHTHALENE DERIVATIVES AND THEIR USE | CBR3, SCO2, CBR1 | CYP2A6 771/4885CYP1A2 297/4885TDP1 3348/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.